Clinical Trials on Tumor Lysis Syndrome

Total 49806 results

Sanofi

Completed

Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy

Hyperuricemia | Tumor Lysis Syndrome | Tumors

United States
Sanofi

Completed

Fasturtec TLS Treatment / Prophylysis

Tumor Lysis Syndrome

United States
Menarini Group

Terminated

Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults (FLORET)

Tumor Lysis Syndrome

Spain, Hungary, Italy, Bulgaria
M.D. Anderson Cancer Center
Sanofi

Completed

Rasburicase in Patients at Risk for Tumor Lysis Syndrome

Tumor Lysis Syndrome

United States
Sanofi

Completed

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

Cancer | Hyperuricemia | Tumor Lysis Syndrome

United States
Sanofi

Terminated

Elitek (Rasburicase) Immuno-Monitoring Study

Tumor Lysis Syndrome

United States
Sanofi

Completed

Rasburicase in Tumor Lysis Syndrome

Hyperuricemia

Brazil
Sanofi

Completed

Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome

Hyperuricemia

Korea, Republic of
M.D. Anderson Cancer Center
Sanofi

Completed

Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2

Lymphoma | Leukemia

United States
M.D. Anderson Cancer Center
Sanofi

Completed

Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS

Lymphoma | Leukemia | Tumor Lysis Syndrome

United States
M.D. Anderson Cancer Center

Active, not recruiting

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Tumor Lysis Syndrome

United States
Menarini Group

Completed

Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies (FLORENCE)

Tumor Lysis Syndrome
St. Jude Children's Research Hospital
Sanofi

Completed

Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients

Lymphoma | Leukemia | Hyperuricemia | Tumor Lysis Syndrome

United States
M.D. Anderson Cancer Center

Recruiting

An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors

Carcinoid Tumor | Carcinoid Syndrome | Metastatic Carcinoid Tumor | Digestive System Neuroendocrine Tumor G1

United States
Crinetics Pharmaceuticals Inc.

Active, not recruiting

Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome

Carcinoid Tumor | Carcinoid Syndrome | Carcinoid | Carcinoid Tumor of Ileum | Carcinoid Tumor of Cecum | Carcinoid Syndrome Diarrhea | Carcinoid Intestine Tumor | Carcinoid Tumor of Liver | Carcinoid Tumor of Pancreas

United States, Brazil, Argentina, Canada, Mexico, Peru, Poland
Advanced Accelerator Applications

Completed

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours (NETTER-1)

Carcinoid Tumor of the Small Bowel | Neuroendocrine Tumour

United States, United Kingdom, Italy, Belgium, France, Germany, Portugal, Spain
Vanderbilt-Ingram Cancer Center
Entrinsic Bioscience Inc.

Terminated

Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency

Neuroendocrine Tumor | Carcinoid Syndrome

United States
National Cancer Institute (NCI)

Recruiting

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors

Solid Tumor | Refractory Solid Tumors | Malignant Solid Tumors | Other Neoplasms Solid Tumors | Pediatric Solid Tumor

United States
Jagiellonian University

Completed

Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy

Cushing's Syndrome | Pheochromocytoma | Adrenal Tumor | Conn's Syndrome

Poland
National Cancer Institute (NCI)

Completed

Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors

Metastatic Gastrointestinal Carcinoid Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Regional Gastrointestinal Carcinoid Tumor

United States
Lowell Anthony, MD
Entrinsic Bioscience Inc.

Completed

Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs

Diarrhea | Neuroendocrine Tumors | Carcinoid Syndrome | Carcinoid Tumor of GI System

United States
University Medical Center Goettingen

Recruiting

Pelvic Cancer Registry for Online Adapted Radiotherapy (PRoART)

Pelvic Tumor | Thoracic Tumor

Germany
Ipsen

Terminated

Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome (CAMPANULA)

Carcinoid Syndrome

Spain, Belgium, Ireland, Czechia, Israel, France, United Kingdom, Latvia, Germany, Russian Federation, Slovakia, Italy, Netherlands, Finland, Austria, Poland, Sweden, Ukraine
Ipsen

Terminated

Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome

Malignant Carcinoid Syndrome

United States
Lexicon Pharmaceuticals

Completed

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome

Carcinoid Syndrome

Germany, United Kingdom
Sheffield Teaching Hospitals NHS Foundation Trust
University of Sheffield

Completed

Effects of Serotonin Excess on Bone in Carcinoid Syndrome

Carcinoid Syndrome

United Kingdom
University of California, San Francisco
Sanofi; Genentech, Inc.

Terminated

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

Lung Cancer | Neuroendocrine Tumor | Islet Cell Tumor | Gastrointestinal Carcinoid Tumor | Neoplastic Syndrome

United States
Lexicon Pharmaceuticals

Completed

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy

Carcinoid Syndrome

United States
Lexicon Pharmaceuticals

Completed

TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)

Carcinoid Syndrome

United States, Australia, Belgium, France, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom, Canada, Israel
Boston Medical Center
Amgen

Withdrawn

Study of Panitumumab in the Treatment of Carcinoid Syndrome

Carcinoid Syndrome

United States
University of Wisconsin, Madison

Recruiting

Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

Acute Myeloid Leukemia | Hodgkin Lymphoma | Osteosarcoma | Acute Lymphoblastic Leukemia | Ewing Sarcoma | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Neuroblastoma | Rhabdomyosarcoma | Primitive Neuroectodermal Tumor | Myeloproliferative Syndrome

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Islet Cell Tumor | Gastrointestinal Carcinoid Tumor | Neoplastic Syndrome

United States
Federation Francophone de Cancerologie Digestive

Completed

Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery

Islet Cell Tumor | Gastrointestinal Carcinoid Tumor | Neoplastic Syndrome
Ipsen

Completed

An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome (ELECT)

Carcinoid Syndrome

United States, Turkey, Brazil, India, Ukraine, South Africa, Czechia, Latvia, Poland, Russian Federation, Serbia
Lexicon Pharmaceuticals

Completed

Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms (TELEPATH)

Carcinoid Syndrome

United States, Australia, Belgium, Canada, France, Germany, Israel, Italy, Netherlands, Spain, Sweden, United Kingdom
Lexicon Pharmaceuticals

Completed

Telotristat Etiprate for Carcinoid Syndrome Therapy (TELECAST)

Carcinoid Syndrome

United States, Australia, Belgium, Canada, France, Germany, Israel, Spain, Sweden, United Kingdom, Netherlands
Endo Pharmaceuticals

Terminated

Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome

Carcinoid Syndrome

United States
TerSera Therapeutics LLC

Completed

Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO (RELAX)

Carcinoid Syndrome

United States
Novartis Pharmaceuticals

Completed

Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor (RADIANT-2)

Carcinoid Tumor | Malignant Carcinoid Syndrome

France, Spain, Netherlands, United States, Canada, Sweden, Italy, Australia, Germany, Greece, Belgium, Czech Republic, Slovakia, Finland, United Kingdom
Lexicon Pharmaceuticals

Completed

An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males (LX1606-104)

Carcinoid Syndrome

United Kingdom
Elpiscience Biopharma, Ltd.

Active, not recruiting

A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors

Neoplasms | Solid Tumors | Malignant Tumor

China
Elpiscience Biopharma, Ltd.

Terminated

A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Solid Tumors

Neoplasms | Solid Tumors | Malignant Tumor

China
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

Neuroendocrine Tumor | Gastrinoma | Glucagonoma | Insulinoma | Metastatic Gastrointestinal Carcinoid Tumor | Pancreatic Polypeptide Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma | WDHA Syndrome

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Gene Expression Profiles to Categorize Wilms Tumors

Recurrent Wilms Tumor and Other Childhood Kidney Tumors | Stage III Wilms Tumor | Stage IV Wilms Tumor | Stage V Wilms Tumor | Stage I Wilms Tumor | Stage II Wilms Tumor

United States
Ipsen

Completed

Study to Evaluate the Use of Resources and the Costs Associated With Carcinoid Syndrome (CS) in Patients With NETs in Spain (RECOSY)

Neuroendocrine Tumors

Spain
Dana-Farber Cancer Institute
Massachusetts General Hospital; Novartis; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital

Completed

Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Neuroendocrine Tumor | Carcinoid Tumor | Pancreatic Neuroendocrine Tumor

United States
Ipsen

Completed

A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea (SYMNET)

Neuroendocrine Tumors | Carcinoid Syndrome

France, Italy, United Kingdom, Poland, Spain, Hungary, Czechia, Israel
Roswell Park Cancer Institute
NeuroEndocrine Tumor Research Foundation (NETRF)

Recruiting

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

Lung Atypical Carcinoid Tumor | Metastatic Pancreatic Neuroendocrine Tumor | Lung Typical Carcinoid Tumor

United States
Chandrikha Chandrasekhara
TerSera Therapeutics LLC

Withdrawn

Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl (NET-PACS)

Diarrhea | Neuroendocrine Tumors | Carcinoid Syndrome

United States
Cliniques universitaires Saint-Luc- Université...

Terminated

Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation (SCIROCCO)

Neuroendocrine Tumors | Carcinoid Syndrome

Clinical Trials on Tumor Lysis Syndrome

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kuwait

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations